News & Articles

AstraZeneca anticipates entering clinical development in 2021

The technology is said to be superior at identifying cell types in human blood, providing faster and more reliable assessments for clinical decision making

In the research, the high-speed tests, which do not require a laboratory and can be performed in cartridges smaller than a mobile phone

Deep-sea coral reefs face challenges as changes to ocean chemistry triggered by climate change may cause their foundations to become brittle

Hydrogen now isn’t everything that hydrogen could be, writes Mats W. Lundberg, sustainable business manager at Sandvik Materials Technology

The partnership aims to co-market exosome technology as well as the joint development of new exosome based products

The collaboration aims to define threshold for neutralizing antibody sufficient to confer immunity

New indication allows this first FDA-approved biomarker-based test to be used as triage for positive cobas HPV tests run on cobas 6800/8800 Systems in primary screening or co-testing programs

The company will increase production of pipette and automation tips, storage tubes and plates, transfer pipettes, and packaging for vials and bottles

A comprehensive and interactive digital guide, to real-time live-cell imaging and analysis

This new integration strengthens IDBS’ existing preclinical capabilities by seamlessly transferring data and enabling increased regulatory compliance

These findings could lead to new preventative strategies, including diet and lifestyle interventions

A cognitive training tool designed by researchers at WMG, University of Warwick has been proven to help ‘train the brain’ to reduce motion sickness by over 50%

Virus-fighting viperins, part of the human immune system, turn out to have bacterial counterparts that might boost the fight against human disease

Agreements with AstraZeneca and the University of Nebraska Medical Center showcase new workflows to improve the throughput, robustness and standardization of clinical biomarker analysis

The study has uncovered a genetic vulnerability present in nearly 10% percent of all breast cancers tumors